North America Immunosuppressant Drugs Market, 2020-2027
The immunosuppressant drugs market in North America is expected to reach a projected revenue of US$ 63,618.9 million by 2027. A compound annual growth rate of 5.8% is expected of North America immunosuppressant drugs market from 2021 to 2027.
In terms of revenue, North America region accounted for 44.7% of the global immunosuppressant drugs market in 2020.
Globally, North America is projected to lead the regional market in terms of revenue in 2027.
Asia Pacific is the fastest growing regional market and is projected to reach USD 33,976.8 million by 2027.
In March 2020, CDC issued guidelines for dental settings in response to the rising number of cases of COVID-19. As per the guidelines, dental settings were recommended to focus only on emergency & urgent visits and postpone all elective visits.
Guidelines by the various regulatory authorities are anticipated to facilitate safe delivery of dental care during the pandemic. According to the North American Dental Group survey, nearly 71% of the participants were unwilling to visit their dentist for nonemergency care due to the COVID 19 concerns.
Thus, fear psychosis coupled with financial issues related to equipment maintenance & facility rent during the lockdown is anticipated to lead to closure of several small dental offices. In addition, inadequate Personal Protective Equipment (PPE) in the region may also hinder growth.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Immunosuppressant Drugs Market will help companies and investors design strategic landscapes.
Monoclonal Antibodies was the largest segment with a revenue share of 76.01% in 2020.
Horizon Databook has segmented the North America immunosuppressant drugs market based on calcineurin inhibitors, mtor inhibitors, antiproliferative agents, monoclonal antibodies covering the revenue growth of each sub-segment from 2016 to 2027.
In March 2020, CDC issued guidelines for dental settings in response to the rising number of cases of COVID-19. As per the guidelines, dental settings were recommended to focus only on emergency & urgent visits and postpone all elective visits.
Guidelines by the various regulatory authorities are anticipated to facilitate safe delivery of dental care during the pandemic. According to the North American Dental Group survey, nearly 71% of the participants were unwilling to visit their dentist for nonemergency care due to the COVID 19 concerns.
Thus, fear psychosis coupled with financial issues related to equipment maintenance & facility rent during the lockdown is anticipated to lead to closure of several small dental offices. In addition, inadequate Personal Protective Equipment (PPE) in the region may also hinder growth.
North America Immunosuppressant Drugs Market Drug Class Outlook (Revenue, USD Million , 2016-2027)
Calcineurin Inhibitors
mTOR Inhibitors
Antiproliferative Agents
Monoclonal Antibodies
Others
North America Immunosuppressant Drugs Market Application Outlook (Revenue, USD Million , 2016-2027)
Autoimmune Diseases
Organ Transplants
Other Applications
North America Immunosuppressant Drugs Market Route of Administration Outlook (Revenue, USD Million , 2016-2027)
Oral
Injectables
North America Immunosuppressant Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2016-2027)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Reasons to subscribe to Immunosuppressant Drugs Market databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Immunosuppressant Drugs Market databook
Our clientele includes a mix of Immunosuppressant Drugs Market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Immunosuppressant Drugs Market, including forecasts for subscribers. This continent databook contains high-level insights into North America Immunosuppressant Drugs Market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
North America Immunosuppressant Drugs Market, 2016-2027 (US$M)